This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.

Adacel® is only indicated for patients 10-64 years of age.2

*Tetanus, diphtheria, and acellular pertussis.
U.S. Food and Drug Administration

Adacel is a registered trademark of Sanofi Pasteur group, and its subsidiaries.

BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tdap


  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.